Regulatory FDA greenlights Roche’s biomarker blood test for Alzheimer’s PharmaphorumRoche has won US FDA clearance for a blood test that could move Alzheimer's biomarker testing further into primary care.NeuroscienceRead full story pharminent August 25, 2026 (Last updated: August 25, 2026) Pharmaphorum Roche has won US FDA clearance for a blood test that could move Alzheimer’s biomarker testing further into primary care. Neuroscience Read full story Post navigation Previous: FDA places clinical hold on Regenxbio’s RGX-121 in MPS II trialNext: Bausch + Lomb advances dry eye disease drug to Phase 3 despite mid-stage fail Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026